Another Feather In Cap For Orchard’s Gene Therapy Product Following UK PIM designation
Executive Summary
Orchard Therapeutics’ gene therapy product for treating the rare, so called “bubble baby” disease has been granted a “promising innovative medicine” designation under the UK’s early access to medicine scheme. The product already has orphan drug, breakthrough therapy and rare pediatric disease designations in the US.
You may also be interested in...
Fresh Or Frozen? Orchard Aims For Cryopreserved Gene Therapy Approvals Using Pivotal Trials With Fresh Cell Formulations
Orchard aims to submit three ex vivo autologous gene therapies for approval by the end of 2021, helped by a new regenerative medicine advanced therapy designation (for a rare primary immunodeficiency syndrome) and a breakthrough therapy designation (for another rare primary immunodeficiency).
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.